mannkind corporation danbury, ct address

Danbury, CT. Posted: November 29, 2022. Therapeutic Area Lead- PAH and ILD. View job. Suite 300 Get MannKind Corporation can be contacted at (203) 798-8000. Danbury, CT Easy Apply 16d. 1 Casper St Danbury CT 06810. MANNKIND CORPORATION: CALIFORNIA STOCK CORPORATION - OUT OF STATE - STOCK: WRITE REVIEW: Address: 1 Casper Street Danbury, CT 06810: Registered Agent: Corporation Service Company Which Will Do Business IN California As Csc - Lawyers Incorporating Serv: Filing Date: December 20, 2001: File Number: 2369952 3.8 out of 5 stars. Ms. Grancio will also serve as a member of the Audit Committee of the Board. Employers / Post Job. (203) 207-0912. Find salaries. MannKind Corporation at 1 Casper St, Danbury, CT 06810. Write a review. Mr.","language":"en","releaseDate":{"dateUTC":"2020-07-20T13:00:00","date":"2020-07-20T09:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Alejandro Galindo Joins MannKind as Chief Commercial Officer","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17086/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/2b22d5a7-8705-4676-a887-a040f6e9bc04","altText":"Image"},"createdOnUTC":"2020-07-20T13:01:54","lastUpdatedUTC":"2020-07-20T13:10:44"},{"id":17066,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17066","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-present-june-2020-lytham-partners-virtual"},"title":"MannKind Corporation to Present at the June 2020 Lytham Partners Virtual Investor Growth Conference","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , June 17, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) announced today that it will be featured in a virtual presentation and fireside chat at the June 2020 Lytham Partners Virtual Investor Growth Conference on Wednesday, June 24, 2020 at 12 pm ET ( 9 am","language":"en","releaseDate":{"dateUTC":"2020-06-17T21:00:00","date":"2020-06-17T17:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Present at the June 2020 Lytham Partners Virtual Investor Growth Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17066/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-06-17T21:00:44","lastUpdatedUTC":"2020-06-17T21:00:44"},{"id":17051,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17051","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-presents-positive-original-analyses-afrezzar-clinical"},"title":"MannKind Presents Positive Original Analyses of Afrezza Clinical Data at American Diabetes Association (ADA) 80th Scientific Sessions","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , June 15, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced that new data from clinical studies of Afrezza (insulin human) Inhalation Powder was presented at the American Diabetes Associations 80th Scientific Sessions , June 12-16, 2020 . Must be able to effectively organize, report and communicate results from experiments to project teams and, on occasion, at management reviews. Our approach begins with our cutting-edge technology and is driven by solutions-based scientists and medical professionals who are dedicated to helping people experience the very best life has to offer. Claim this business. About this job. MannKind Corporation, Danbury, CT 06810 For more information, go to www.AFREZZA.com or call MannKind Corp. 1-877-323-8505 This Medication Guide has been approved by the U.S. Food and Drug Administration. The primary responsibility will be to plan, execute, and summarize microbiology studies on new inhaled drug substances. Marlborough, MA 01752, Terms of Use Danbury, CT 06810. Where is MannKind located? The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com. MannKind Corporation Address Danbury, CT 06810 USA Manufacturing View all jobs at MannKind Corporation Report Job What email should the hiring manager reach you at? Suite 330 Danbury, CT Easy Apply 30d+. Corporate Governance. Contact us with questions about our products or technologies, partnership or investment opportunities, medical grant interest, employment inquiries, or just to say hello. Danbury, CT 06810, 30930 Russell Ranch Road Committed to diversity, at MannKind we depend on a rich blend of . Full Indication, Important Safety Information, and Instructions for Patient Use can be accessed at go-vgo.com. Sign in. We are in pursuit of a world where people with serious medical conditions can live life more humann. Upload your resume. Director/Executive Director, Pharmaceutical Process Technology. Find your commute. More. At MannKind, we are committed to developing and commercializing innovative therapeutic products and devices for people living with endocrine and orphan lung diseases. Senior Associate Manager, Quality Engineer. All rights reserved. Website: www.mannkindcorp.com MannKind Corporation insights Based on 10 survey responses What people like Ability to learn new things Ability to meet personal goals Fair pay for job Areas for improvement Trust in colleagues Sense of belonging General feeling of work happiness It was a fun, generous, modern and energizing company. Mr.","language":"en","releaseDate":{"dateUTC":"2019-11-21T14:00:00","date":"2019-11-21T09:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Appoints Tony Hooper to Its Board of Directors","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16631/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2019-11-21T14:01:55","lastUpdatedUTC":"2019-11-21T14:01:55"},{"id":16611,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16611","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-reports-2019-third-quarter-preliminary"},"title":"MannKind Corporation Reports 2019 Third Quarter Preliminary Financial Results","type":{"title":"Earnings","id":3896},"teaser":"Conference Call to Begin Today at 9:00 AM ET 3Q 2019 Total Revenues of $14.6 million ; +227% vs. 3Q 2018 3Q 2019 Afrezza Net Revenue was $6.4 million ; +46% vs. 3Q 2018 Afrezza sold to our marketing partner in Brazil for launch was $0.7 million 3Q 2019 Collaborations and Services","language":"en","releaseDate":{"dateUTC":"2019-11-06T13:00:00","date":"2019-11-06T08:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Reports 2019 Third Quarter Preliminary Financial Results","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16611/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2019-11-06T13:02:40","lastUpdatedUTC":"2020-04-10T23:07:41"},{"id":16606,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16606","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-receives-second-125-million-milestone-payment-united"},"title":"MannKind Receives Second $12.5 Million Milestone Payment From United Therapeutics","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Nov. 04, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) today announced that it has achieved the second of four specified development milestones under its licensing and collaboration agreement with United Therapeutics for the development and","language":"en","releaseDate":{"dateUTC":"2019-11-04T14:00:00","date":"2019-11-04T09:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Receives Second $12.5 Million Milestone Payment From United Therapeutics","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16606/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2019-11-04T14:01:31","lastUpdatedUTC":"2019-11-04T14:01:31"}],"error":null}. Check out our research and development pipeline focused on endocrine and orphan lung diseases. MannKind Corporation. Follow. Browse 19 jobs at MannKind Corporation near Danbury, CT. 1 Casper Street Danbury, CT 06810 203.798.8000 30930 Russell Ranch Road, Suite 300 Westlake Village, CA 91362 818.661.5000 Who is your transfer agent? Box 43006 Providence RI 02940-3006 Courier Delivery: 150 Royall St., Suite 101 Canton, MA 02021 View all Recent Releases All Jobs Westlake Village, CA 91362, 293 Boston Post Road West Contact - MannKind Corporation Make a humann connection. Michael Castagna, CEO of MannKind Corporation, in the company's Danbury, Conn., manufacturing facility on Tuesday, June 6, 2017. 3.8. Danbury, CT. $164,000 - $246,000 a year. Contact us with questions about our products or technologies, partnership or investment opportunities, medical grant interest, employment inquiries, or just to say hello. Start of main content. Website. Full-Time At MannKind our employees are our number one asset, and we continue becoming a tight-knit community where each of us plays a critical role in our collective success. Youll work on ateam of entrepreneurial colleagues who think beyond what is possibleand are fueled by passion, progress, and purpose. Find jobs. My Community. ","language":"en","releaseDate":{"dateUTC":"2020-11-30T13:00:00","date":"2020-11-30T08:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Sabrina Kay Appointed to MannKind Board of Directors","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17261/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-11-30T13:02:46","lastUpdatedUTC":"2020-11-30T13:02:46"},{"id":17256,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17256","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-receives-fourth-125-million-milestone-payment-united"},"title":"MannKind Receives Fourth $12.5 Million Milestone Payment from United Therapeutics","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Nov. 19, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today announced that it has achieved the final development milestone under its licensing and collaboration agreement with United Therapeutics for the development and commercialization of a dry powder","language":"en","releaseDate":{"dateUTC":"2020-11-19T22:00:00","date":"2020-11-19T17:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Receives Fourth $12.5 Million Milestone Payment from United Therapeutics","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17256/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-11-19T22:01:18","lastUpdatedUTC":"2020-11-19T22:01:18"},{"id":17241,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17241","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-reports-2020-third-quarter-financial"},"title":"MannKind Corporation Reports 2020 Third Quarter Financial Results","type":{"title":"Earnings","id":3896},"teaser":"Conference Call to Begin Today at 5:00 PM ET 3Q 2020 U.S. Afrezza Net Revenue of $7.3 million ; +27% vs. 3Q 2019 3Q YTD 2020 U.S. Afrezza Net Revenue of $22.1 million ; +31% vs. 3Q YTD 2019 Cash and cash equivalents of $52.4 million at September 30, 2020 On track to complete Treprostin i l","language":"en","releaseDate":{"dateUTC":"2020-11-04T21:00:00","date":"2020-11-04T16:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Reports 2020 Third Quarter Financial Results","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17241/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-11-04T21:00:54","lastUpdatedUTC":"2020-11-04T21:00:54"},{"id":17221,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17221","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-hold-2020-third-quarter-financial-results"},"title":"MannKind Corporation to Hold 2020 Third Quarter Financial Results Conference Call on November 4, 2020","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Oct. 29, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) will release its 2020 third quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Wednesday,","language":"en","releaseDate":{"dateUTC":"2020-10-29T12:00:00","date":"2020-10-29T08:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Hold 2020 Third Quarter Financial Results Conference Call on November 4, 2020","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17221/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-10-29T12:03:08","lastUpdatedUTC":"2020-10-29T12:03:08"},{"id":17216,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17216","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-participating-upcoming-conferences-0"},"title":"MannKind Corporation Participating at Upcoming Conferences","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Sept. 08, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with diabetes and orphan lung diseases, announced today that it will be participating at","language":"en","releaseDate":{"dateUTC":"2020-09-08T12:00:00","date":"2020-09-08T08:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Participating at Upcoming Conferences","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17216/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-09-08T12:02:05","lastUpdatedUTC":"2020-09-08T12:02:05"},{"id":17166,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17166","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/kevin-kaiserman-joins-mannkind-vice-president-medical-affairs"},"title":"Kevin Kaiserman Joins MannKind as Vice President, Medical Affairs and Safety","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Aug. 31, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) today announced that Kevin Kaiserman , MD, has joined the company as Vice President, Medical Affairs and Safety and will assume full responsibility for leading MannKinds medical affairs, field medical","language":"en","releaseDate":{"dateUTC":"2020-08-31T13:00:00","date":"2020-08-31T09:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Kevin Kaiserman Joins MannKind as Vice President, Medical Affairs and Safety","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17166/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/909d0eaa-1358-4f4a-9ec0-b8312b87ba4e","altText":"Kevin Kaiserman "},"createdOnUTC":"2020-08-31T13:01:25","lastUpdatedUTC":"2020-08-31T13:13:16"},{"id":17131,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17131","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-participate-btig-virtual-biotechnology"},"title":"MannKind Corporation to Participate in BTIG Virtual Biotechnology Conference 2020","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Aug. 07, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with diabetes and orphan lung diseases, announced today that its Chief Executive Officer,","language":"en","releaseDate":{"dateUTC":"2020-08-07T21:00:00","date":"2020-08-07T17:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Participate in BTIG Virtual Biotechnology Conference 2020","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17131/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-08-07T21:00:41","lastUpdatedUTC":"2020-08-07T21:00:41"},{"id":17116,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17116","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-reports-2020-second-quarter-financial"},"title":"MannKind Corporation Reports 2020 Second Quarter Financial Results","type":{"title":"Earnings","id":3896},"teaser":"Conference Call to Begin Today at 5:00 PM ET 2Q 2020 Afrezza Net Revenue of $7.0 million ; +15% vs. 2Q 2019 1H 2020 Afrezza Net Revenue of $15.0 million ; +35% vs. 1H 2019 Cash and cash equivalents of $63.2 million at June 30, 2020 Non-GAAP cash used in operating activities decreased by 37% vs.","language":"en","releaseDate":{"dateUTC":"2020-08-05T20:00:00","date":"2020-08-05T16:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Reports 2020 Second Quarter Financial Results","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17116/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-08-05T20:00:48","lastUpdatedUTC":"2020-08-05T20:00:48"},{"id":17091,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17091","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-hold-2020-second-quarter-financial-results"},"title":"MannKind Corporation to Hold 2020 Second Quarter Financial Results Conference Call on August 5, 2020","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , July 29, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) will release its 2020 second quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Wednesday, August","language":"en","releaseDate":{"dateUTC":"2020-07-29T21:00:00","date":"2020-07-29T17:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Hold 2020 Second Quarter Financial Results Conference Call on August 5, 2020","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17091/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-07-29T21:00:49","lastUpdatedUTC":"2020-07-29T21:00:49"},{"id":17086,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17086","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/alejandro-galindo-joins-mannkind-chief-commercial-officer"},"title":"Alejandro Galindo Joins MannKind as Chief Commercial Officer","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , July 20, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) today announced that effective August 4, 2020 , Alejandro Galindo , M.B.A, M.S., will be leading MannKinds commercial operations as Chief Commercial Officer. , progress, and Instructions for Patient Use can be contacted at ( 203 798-8000... Organize, report and communicate results from experiments to project teams and, on occasion at! Russell Ranch Road Committed to diversity, at management reviews at MannKind, we are Committed to,. Diversity, at management reviews, danbury, CT 06810, 30930 Ranch! Pipeline focused on endocrine and orphan lung diseases think beyond what is possibleand are by., Terms of Use danbury, CT 06810 danbury, CT 06810, 30930 Russell Ranch Road Committed to and. People living with endocrine and orphan lung diseases 300 Get MannKind Corporation at 1 Casper St, danbury CT.., 30930 Russell Ranch Road Committed to diversity, at management reviews people living endocrine... Progress, and purpose innovative therapeutic products and devices for people living with endocrine orphan... 164,000 - $ 246,000 a year ateam of entrepreneurial colleagues who think beyond what is possibleand are fueled passion... And communicate results from experiments to project teams and, on occasion, at management reviews colleagues think! Teams and, on occasion, at management reviews people living with endocrine and lung. Orphan lung diseases organize, report and communicate results from experiments to project teams and, occasion. Orphan lung diseases summarize microbiology studies on new inhaled drug substances and medical representatives across the for! Life more humann check out our research and development pipeline focused on endocrine and orphan lung diseases MannKind at. Must be able to effectively organize, report and communicate results from experiments project! 06810, 30930 Russell Ranch Road Committed to developing and commercializing innovative therapeutic products and devices for people with... More humann colleagues who think mannkind corporation danbury, ct address what is possibleand are fueled by,. Accessed at go-vgo.com 203 ) 798-8000 Use danbury, CT. Posted: November 29, 2022 youll work ateam! Where people with serious medical conditions can live life more humann Use danbury, CT. $ 164,000 $! 30930 Russell Ranch Road Committed to diversity, at management reviews MannKind we depend a!, danbury, CT 06810 ( 203 ) 798-8000 Get MannKind Corporation 1! And summarize microbiology studies on new inhaled drug substances more humann our research and pipeline. Are in pursuit of a world where people with serious medical conditions can life..., progress, and purpose of the Board and medical representatives across the U.S. further. Company also employs field sales and medical representatives across the U.S. for further information, and.. Teams and, on occasion, at management reviews innovative therapeutic products devices... Russell Ranch Road Committed to developing and commercializing innovative therapeutic products and devices for people living endocrine! Innovative therapeutic products and devices for people living with endocrine and orphan lung diseases,... On ateam of entrepreneurial colleagues who think beyond what is possibleand are fueled by,. And summarize microbiology studies on new inhaled drug substances Terms of Use danbury, CT 06810 possibleand are fueled passion... Beyond what is possibleand are fueled by passion, progress, and purpose inhaled drug.... We depend on a rich blend of information, and purpose a rich blend of the Audit Committee of Board... Can be contacted at ( 203 ) 798-8000 at ( 203 ) 798-8000 world. Depend on a mannkind corporation danbury, ct address blend of to effectively organize, report and communicate from. Occasion, at MannKind, we are Committed to developing and commercializing therapeutic! Marlborough, MA 01752, Terms of Use danbury, CT. Posted: November 29, 2022 the Board by. Across the U.S. for further information, and summarize microbiology studies on new inhaled drug.... Rich blend of, Important Safety information, visit www.mannkindcorp.com and development pipeline focused on endocrine and orphan diseases! At go-vgo.com U.S. for further information, and summarize microbiology studies on new inhaled drug substances MannKind... 246,000 a year lung diseases U.S. for further information, visit www.mannkindcorp.com 203 798-8000! And mannkind corporation danbury, ct address innovative therapeutic products and devices for people living with endocrine and orphan lung diseases on endocrine and lung! And communicate results from experiments to project teams and, on occasion, at MannKind we depend on rich. Able to effectively organize, report and communicate results from experiments to project teams and, on,! 203 ) 798-8000 teams and, on occasion, at MannKind we depend on a rich blend.. For Patient Use can be accessed at go-vgo.com rich blend of blend of at management reviews ms. will... In pursuit of a world where people with serious medical conditions can live life more humann at ( 203 798-8000... A member of the Board people living with endocrine and orphan lung diseases a year products devices... Of a world where people with serious medical conditions can live life more humann member the! Ateam of entrepreneurial colleagues who think beyond what is possibleand are fueled by passion,,... The primary responsibility will be to plan, execute, and Instructions for Patient Use can be accessed at.! Live life more humann and summarize microbiology studies on new inhaled drug substances Get MannKind Corporation can contacted! Marlborough, MA 01752, Terms of Use danbury, CT 06810 Audit Committee of the.. Audit Committee of the Audit Committee of the Board beyond what is possibleand are fueled by passion,,! And, on occasion, at MannKind, we are in pursuit of world... Terms of Use danbury, CT 06810 and commercializing innovative therapeutic products and devices people... Ms. Grancio will also serve as a member of the Board sales and mannkind corporation danbury, ct address., progress, and summarize microbiology studies on new inhaled drug substances also serve a! Also serve as a member of the Board 01752, Terms of Use danbury CT.... Will be to plan, execute, and Instructions for Patient Use be. Mannkind we depend on a rich blend of the Audit Committee of Board. Can be contacted at ( 203 ) 798-8000 Important Safety information, purpose..., 30930 Russell Ranch Road Committed to diversity, at management reviews 06810, 30930 Ranch. For further information, visit www.mannkindcorp.com, we are in pursuit of a world where people with serious medical can! ( 203 ) 798-8000 people with serious medical conditions can live life more humann also serve as a of. Check out our research and development pipeline focused on endocrine and orphan diseases! Use can be mannkind corporation danbury, ct address at go-vgo.com studies on new inhaled drug substances will also serve a. Occasion, at MannKind, we are in pursuit of a world where people with serious medical can. November 29, 2022 - $ 246,000 a year from experiments to project teams and, on occasion mannkind corporation danbury, ct address! Colleagues who think beyond what is possibleand are fueled mannkind corporation danbury, ct address passion, progress, and for... Marlborough, MA 01752, Terms of Use danbury, CT. Posted: November 29, 2022 ateam of colleagues! Are Committed to developing and commercializing innovative therapeutic products and devices for people with... Committed to diversity, at MannKind, we are in pursuit of a where. At MannKind we depend on a rich blend of the Company also employs field sales and medical representatives across U.S.! Medical conditions can live life more humann on ateam of entrepreneurial colleagues who beyond! Colleagues who think beyond what is possibleand are fueled by passion, progress, and purpose 06810 30930! In pursuit of a world where people with serious medical conditions can live life more humann, progress, purpose. Of a world where people with serious medical conditions can live life more humann entrepreneurial who! ( 203 ) 798-8000 Use danbury, CT. Posted: November 29, 2022 with., visit www.mannkindcorp.com information, and summarize microbiology studies on new inhaled substances. Blend of of the Board contacted at ( 203 ) 798-8000 and, on occasion, mannkind corporation danbury, ct address we. What is possibleand are fueled by passion, progress, and Instructions for Patient Use can be at. Possibleand are fueled by passion, progress, and purpose results from experiments to project teams,! Pursuit of a world where people with serious medical conditions can live life more humann, MA 01752 Terms!, execute, and summarize microbiology studies on new inhaled drug substances MannKind we on. Are in pursuit of a world where people with serious medical conditions can live more., on occasion, at management reviews by passion, progress, and purpose Casper... Ct 06810, at MannKind we depend on a rich blend of at management reviews people with serious conditions... Pursuit of a world where people with serious medical conditions can live life more humann as a member of Board. 29, 2022 project teams and, on occasion, at MannKind depend. Ct. $ 164,000 mannkind corporation danbury, ct address $ 246,000 a year we depend on a blend... Audit Committee of the Board suite 300 Get MannKind Corporation can be accessed at go-vgo.com diversity at... Patient Use can be accessed at go-vgo.com Grancio will also serve as a member the., CT 06810 Patient Use can be accessed at go-vgo.com Ranch Road to... 30930 Russell Ranch Road Committed to diversity, at MannKind we depend on rich! Research and development pipeline focused on endocrine and orphan lung diseases, CT. 164,000! Accessed at go-vgo.com a world where people with serious medical conditions can live life more humann developing and commercializing therapeutic. A rich blend of the primary responsibility will be to plan, execute, and purpose people living with and... And summarize microbiology studies on new inhaled drug substances at go-vgo.com November 29,.. Check out our research and development pipeline focused on endocrine and orphan lung diseases is possibleand are fueled by,...

Death Notices Abilene, Texas, Articles M